The effect of advanced glycation end-products and aminoguanidine on TNFα production by rat peritoneal macrophages

Peritoneal Dialysis International

Volumn 21, Issue 2, 2001, Pages 122-129

  Rashid, Gloria ^b   Luzon, Ami Ad ^b   Korzets, Ze'ev ^b   Klein, Osnat ^b   Zeltzer, Ella ^b   Bernheim, Jacques ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Advanced glycation end products (AGEs); Aminoguanidine; Peritoneal macrophages; TNF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BUFFER; GLUCOSE; LIPOPOLYSACCHARIDE; PERITONEAL DIALYSIS FLUID; PHOSPHATE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFLUENT; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT;

EID: 0035020519     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102100203     Document Type: Article

References (48)

1. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1991; 11:14-21.
2. Brulez HFH, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15(7, Suppl):S24-34.
3. Verburg HA, Keane WE, Hoidal JR, Freiberg MR, Elliot GR, Petersen PK. Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis 1983; 147: 1018-29.
4. Mackenzie RK, Coles GA, Williams JD. The response of human peritoneal macrophages to stimulation with bacteria isolated from episodes of continuous ambulatory peritoneal dialysis-related peritonitis. J Infect Dis 1991; 163:837-42.
5. Vanholder R, Lameire N, Waterloos MA, Van Landschoot N, De Smet R, Vogeleere P, et al. Disturbed host defense in peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. Kidney Int 1996; 50:643-52.
6. Topley N, Alobaidi HM, Davis M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34:404-11.
7. Douvdevani A, Rapoport J, Konforti A, Zlotnik M, Chaimovitz C. The effect of peritoneal dialysis fluid on the release of IL-1β and TNFα by macrophage/monocytes. Perit Dial Int 1993; 13:112-17.
8. Bos HJ, Vlaanderen K, Van der Mulen J, De Veld J, Ole LP, Beelen RHJ. Peritoneal macrophages in short dwell time effluent show diminished phagocytosis. Perit Dial Int 1988; 8:199-202.
9. Bos HJ, Van Bronswijk H, Helmerhorst TJM, Oe PL, Hoefsmit ECM, Beelen RHJ. Distinct subpopulations of elicited human macrophages in peritoneal dialysis patients and women undergoing laparoscopy: a study of peroxidatic activity. J Leukoc Biol 1988; 43:172-8.
10. Bos HJ, Meyer F, de Veld JC. Peritoneal fluid induces change of mononuclear phagocyte proportions. Kidney Int 1989; 36:20-6.
11. Vlassara H, Bucala R, Striker L. Biology of disease. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70:138-51.
12. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
13. Raj DSC, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000; 35:365-80.
14. Lamb E. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995; 47:1768-74.
15. Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis. Am J Kidney Dis 1990; 15:97-109.
16. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stren D. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14:1521-8.
17. Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82:5588-92.
18. Takata K, Horiuchi S, Araki M, Shiga M, Saitoh M, Morno Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988; 29:14819-25.
19. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87:9010-14.
20. Westwood ME, McLellan AC, Thornalley PJ. Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. J Biol Chem 1994; 269:32293-8.
21. Imani F, Hori Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, et al. Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-γ: role in tissue remodeling. J Med 1993; 178: 2165-72.
22. Skolnik ER, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174:931-9.
23. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164:1301-9.
24. Radoff S, Cerami A, Vlassara H. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes 1990; 39:1510-18.
25. Troncoso IA, Esteban MM, Ruiz MA, Florez L, Bareneo L. In vitro advanced glycation end product formation in rat tail tendon fibers: influence of aminoguanidine. Transplant Proc 1995; 27:3345-6.
26. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper M. Effect of aminoguanidine therapy on renal advanced glycation end products. Kidney Int 1999; 55:907-16.
27. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysosome and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1:1057-61.
28. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267:5133-8.
29. Nakayama H, Mitsuhashi T, Itoh T, Kuwajima S, Aoki S, Kuroda Y, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 1993; 42:345-50.
30. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, et al. N (epsilon)-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996; 35: 8075-83.
31. Lewis SL, Norris PJ, Holmes C. Phenotypic characterization of monocytes and macrophages from CAPD patients. ASATO Trans 1990; 36:M575-7.
32. Zemel D, Krediet RT. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Blood Purif 1996; 14:198-216.
33. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
34. Floege J, Lonnemann G, Shaldon S, Deschot G, Slingeneyer A, Mion C, et al. Is tumor necrosis factor (TNF) produced in the peritoneal cavity of asymptomatic CAPD patients? Kidney Int 1989; 35:270.
35. Douvdevani A, Rapoport J, Konforty A, Yuzari R, Moran A, Chaimovitz C. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol 1995; 6:207-13.
36. de Fijter CW, Verburg HA, Oe LP, Heezius E, Donker AJ, Verhoef J, et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21:411-18.
37. de Fijter CWH, Verburg HA, Peters EDH, Oe LP, van der Meulen J, Verhoef J, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39:75-80.
38. i) and TNFα production by peritoneal macrophages. Perit Dial Int 1997; 17:546-53.
39. Mackenzie RK, Jones S, Moseley A, Holmes CH, Argyle R, Williams JD, et al. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis 2000; 35:112-21.
40. Friedlander MA, Hubert CM, Wu YC, Rich EA. Role of dialysis modality in responses of blood monocytes and peritoneal macrophages to endotoxin stimulation. Am J Kidney Dis 1993; 22:11-23.
41. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
42. Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakano H, Nazaki O, et al. Immunohistochemical study of human advanced glycosylation end-products in chronic renal failure. Clin Nephrol 1994; 42:354-61.
43. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachecin/TNF and IL-1 induced by glucose-modified proteins: role in tissue remodeling. Science 1988; 240:1546-8.
44. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci 1995; 748:562-70.
45. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I (IGF-I) in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90: 439-46.
46. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40:1007-12.
47. Wrenger E, Baumann C, Behrend M, Zamore E, Schindler R, Brunkhorst R. Peritoneal mononuclear cell differentiation and cytokine production in intermittent and continuous automated peritoneal dialysis. Am J Kidney Dis 1998; 31:234-41.
48. McGregor SJ, Topley N, Jörres A, Speekenbrink ABJ, Gordon A, Gahl GM, et al. Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: maturity, cytokine synthesis and arachidonic acid metabolism. Kidney Int 1996; 49:525-33.